Keymed Biosciences Inc. (HKG:2162)
Hong Kong · Delayed Price · Currency is HKD 72.50
-2.75 (-3.65%)
Jul 30, 2026, 3:40 PM HKT
Keymed Biosciences Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 716.31 | 716.31 | 428.12 | 354.1 | 100.06 | 110.27 |
Revenue Growth | -17.87% | 67.31% | 20.91% | 253.87% | -9.26% | - |
Gross Profit Gross Profit Growth | 627.06 | 627.06 | 415.92 | 317.22 | 97.48 | 93.07 |
Operating Income Operating Income Growth | -631.05 | -631.05 | -626.09 | -457.43 | -544.49 | -360.5 |
Net Income Net Income Growth | -522.64 | -522.64 | -515.24 | -359.36 | -308.12 | -3,887 |
Earnings Per Share EPS Growth | -1.91 | -1.91 | -1.97 | -1.37 | -1.18 | -24.17 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
United States of America United States of America Growth | 393.67 | 393.67 | 335.01 | - | - | - |
Mainland China Mainland China Growth | 322.17 | 322.17 | 36.97 | 0.9 | 100.06 | 110.27 |
United Kingdom United Kingdom Growth | 0.47 | 0.47 | 56.14 | - | - | - |
Total Total Growth | 716.31 | 716.31 | 428.12 | 354.1 | 100.06 | 110.27 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 1,924 | 1,924 | 2,156 | 2,719 | 3,175 | 3,525 |
Total Debt Total Debt Growth | 788.54 | 788.54 | 753.24 | 418.71 | 122.19 | 39.26 |
Net Cash (Debt) Net Cash Growth | 1,135 | 1,135 | 1,402 | 2,300 | 3,053 | 3,485 |
Net Cash Growth | -40.99% | -19.05% | -39.04% | -24.65% | -12.40% | - |
Net Cash Per Share Net Cash Per Share Growth | 4.14 | 4.14 | 5.35 | 8.80 | 11.69 | 21.67 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -712.41 | -712.41 | -789.63 | -303.62 | -401.93 | -214.64 |
Capital Expenditures CapEx Growth | -333.92 | -333.92 | -207.91 | -378.49 | -278.82 | -171.79 |
Free Cash Flow Free Cash Flow Growth | -1,046 | -1,046 | -997.55 | -682.11 | -680.76 | -386.42 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 87.54% | 87.54% | 97.15% | 89.59% | 97.42% | 84.40% |
Operating Margin | -88.10% | -88.10% | -146.24% | -129.18% | -544.15% | -326.93% |
Pretax Margin | -72.69% | -72.69% | -118.81% | -100.59% | -303.41% | -3530.12% |
Profit Margin | -72.96% | -72.96% | -120.35% | -101.49% | -307.92% | -3525.30% |
FCF Margin | -146.07% | -146.07% | -233.00% | -192.63% | -680.33% | -350.44% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 27.81 | 19.75 | 18.69 | 34.83 | 125.30 | 71.30 |